Decursin‐Loaded Nanovesicles Target Macrophages Driven by the Pathological Process of Atherosclerosis

• DOI: 10.1002/advs.202417489
• Publication Date: 2025-04-26T11:34:03Z
• Authors: Hui Chen; Yifeng Zhang; Mirenuer Aikebaier; Yawei Du; Yan Liu; Qing Zha; Lan Zheng; Shuyao Shan; Yanping Wang; Jiawei Chen; Yiping Li; Ke Yang; Ying Yang; Wenguo Cui
• Keywords: Internalization; Foam cell

Abstract Atherosclerosis (AS) is a major pathological factor contributing to the mortality associated with ischemic heart disease and driven primarily by macrophage‐mediated lipid accumulation inflammatory processes. Conventional cardiovascular pharmacotherapies address these mechanisms but often show limited efficacy, highlighting need for innovative agents capable of effectively reducing inflammation minimal toxicity. In this study, decursin, monomer derived from traditional Chinese medicine, shown inhibit both responses in macrophages through direct interaction protein kinase Cδ (PKCδ), resulting low cytotoxicity vitro negligible toxicity vivo. To short half‐life targeted cascade drug delivery system (ALD@EM), which specifically designed target AS pathophysiology, developed. This employs ICAM‐1 VCAM‐1 antibodies plaque localization incorporates low‐density lipoproteins (LDLs) facilitate chemotaxis lesion sites, an inner layer apoptotic endothelial cell membranes increase macrophage internalization release. As result, ALD@EM nanovesicles significantly increased therapeutic efficacy decursin within plaques, substantially deposition inflammation, thereby offering novel strategy treatment.